Evidence map›Paper›PMID 36789386›Full record

ArticleHeliyon2023

Performance characteristics of the boson rapid SARS-cov-2 antigen test card vs RT-PCR: Cross-reactivity and emerging variants.

Michail Leventopoulos, Vassiliki Michou, Chrysoula Kyprianidou, Christos Meristoudis, Nikolaos George Manias, Harilaos Panagiotis Kavvadas, Dimitris Nikolopoulos, Vassilis Tsilivakos, Georgios Georgoulias

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michail LeventopoulosDepartment of Cellular Biology and Immunology, Locus Medicus S.A., Athens, Greece.
Vassiliki MichouDepartment of Molecular Pathology and Genetics, Locus Medicus S.A., Athens, Greece.
Chrysoula KyprianidouDepartment of Molecular Pathology and Genetics, Locus Medicus S.A., Athens, Greece.
Christos MeristoudisDepartment of Molecular Pathology and Genetics, Locus Medicus S.A., Athens, Greece.
Nikolaos George ManiasDepartment of Statistics, Locus Medicus S.A., Athens, Greece.
Harilaos Panagiotis KavvadasDepartment of Cellular Biology and Immunology, Locus Medicus S.A., Athens, Greece.
Dimitris NikolopoulosDepartment of Cellular Biology and Immunology, Locus Medicus S.A., Athens, Greece.
Vassilis TsilivakosDepartment of Cellular Biology and Immunology, Locus Medicus S.A., Athens, Greece.
Georgios GeorgouliasDepartment of Biopathology, Locus Medicus S.A., Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: SARS-CoV-2 virus has undergone several mutations on its genome, since the onset of the pandemic. Multiple variants of concern (VOC) have emerged including Alpha, Beta, Gamma, and Delta with the more recent one being the Omicron (B.1.1.529). Specific rapid antigen tests (RADs) have been used for the detection of SARS-CoV-2. However, since the emergence of new VOCs, the performance characteristics of these RADs needs to be re-evaluated. Objectives: The main purposes of this clinical study were to determine the diagnostic sensitivity and specificity of the BOSON Rapid Antigen Test compared to the gold standard real time RT-PCR and to determine the ability of the RAD to accurately depict different VOC. Additionally, the cross reactivity to other viruses and pathogen, as well as, the possible interference of non Covid-19 hospitalized patients for various causes, were investigated. Results: A total of 623 individuals (symptomatic) were tested. The sensitivity, specificity and accuracy of the BOSON RAD was 95.27%, 100% and 98.45% (n = 448), meeting the WHO recommended standards. Additionally, the Delta (83.33%, Ct < 34) and Omicron (100%, Ct < 26) VOC were determined with high sensitivity. Also, there was no interference from hospitalized, non-Covid 19 patients, and no cross-reactivity was detected. Conclusions: The study showed that this RAD could rapidly identify individuals with SARS-CoV-2, including those with the new dominant Omicron VOC, with no cross reactivity from other pathogens.

Indexed as

DeltaOmicronRapid antigen testRT–rtPCRSARS–CoV–2

Identifiers

PMID36789386
PMCPMC9911158
OpenAlexW4319659368

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.